Watch B. Gonska stressing the importance of procedural safety, excellent haemodynamics, valve durability and preserved coronary access when treating younger, low- and intermediate-risk TAVI patients. Navitor™’is presented, reviewing the VANTAGE trial data with single-digit gradients, low complication rates and minimal PVL, confirming Navitor™’s safety and value for lifetime management.